TheranosticTrials.org

Clinical Trial · NCT04023240

68-Ga-FAPI PET Imaging in Malignancy

Overview

This feasibility trial studies the use of gallium-68 (68Ga)-FAPI as the imaging agent for positron emission tomography (PET)/computed tomography (CT), collectively PET/CT, in patients with various cancers. PET uses a radioactive substance called 68Ga-FAPI, which attaches to cancer activated fibroblasts. The PET scanner takes pictures that capture where the radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy tissue. CT uses X-rays to make a picture of areas inside the body. Using 68Ga-FAPI in diagnostic procedures, such as PET/CT, may allow doctors to identify smaller tumors than standard imaging.

Sponsor

Stanford University

Phase

Phase 2

Contacts

Carina A Mari, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04023240

Drug / Compound

FAPI

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

Eligibility

Inclusion

  • Patient with current malignancy confirmed via pathology or imaging
  • Patient of reproductive potential will have a pregnancy test

Exclusion

  • Pregnant or breastfeeding